Ensuring People Living with HIV Inform the Future of HIV Treatment in Low- and Middle-Income Countries: A Scoping Review and Recommendations for a Community-Led Research Agenda.
End User Preferences
HIV Product Attributes
HIV Service Delivery
HIV Treatment
Long-Acting Antiretrovirals
Journal
AIDS and behavior
ISSN: 1573-3254
Titre abrégé: AIDS Behav
Pays: United States
ID NLM: 9712133
Informations de publication
Date de publication:
11 Jul 2024
11 Jul 2024
Historique:
accepted:
01
07
2024
medline:
12
7
2024
pubmed:
12
7
2024
entrez:
11
7
2024
Statut:
aheadofprint
Résumé
The HIV treatment landscape in low- and middle-income countries (LMICs) is rapidly evolving, exemplified by the expansion of differentiated service delivery (DSD) during the coronavirus disease (COVID-19) pandemic. Long-acting products represent a new frontier that will require a significant redesign of health systems. It is critical to understand service delivery and product preferences of people living with HIV (PLHIV) and ensure evidence generation is guided by community priorities. We conducted a scoping review to identify gaps among preference studies and inform future research. Peer-reviewed articles published from January 2014-May 2022 reporting acceptability or preference data from PLHIV or caregivers for one or more service delivery or product attribute were eligible. Service delivery studies were restricted to LMIC populations while product studies had no geographical restrictions. Based on gaps identified, we consulted advocates to develop community-led research agenda recommendations. Of 6,493 studies identified, 225 studies on service delivery attributes and 47 studies on product preferences were eligible. The most frequently studied delivery models were integration (n = 59) and technology-based interventions (n = 55). Among product literature, only 15 studies included LMIC populations. Consultation with advocates highlighted the need for research on long-acting products, including among pediatric, pregnant, and breastfeeding PLHIV, PLHIV on second-line regimens, and key populations. Consultation also emphasized the need to understand preferences on clinic visit frequency, side effects, and choice. While the preference literature has expanded, gaps remain around long-acting regimens and their delivery. To fill these gaps, the research agenda must be guided by the priorities of communities of PLHIV.
Identifiants
pubmed: 38992225
doi: 10.1007/s10461-024-04442-8
pii: 10.1007/s10461-024-04442-8
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Unitaid
ID : Unitaid
Informations de copyright
© 2024. The Author(s).
Références
World Health Organization. Updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. [Internet]. Geneva: World Health Organization, 2021 [cited 2023 March 2]. https://www.who.int/news/item/17-03-2021-who-publishes-new-clinical-recommendations-on-hiv-prevention-infant-diagnosis-antiretroviral-therapy-initiation-and-monitoring .
IAS. Person-centered care stakeholder consultation meeting series, 2022–2023. [Internet]. IAS. 2023. https://www.iasociety.org/sites/default/files/PCC/PCC_Consultation_Summary_Report_AIDS_2022_final.pdf .
Boyd AT, Jahun I, Dirlikov E, et al. Expanding access to HIV services during the COVID-19 pandemic—Nigeria, 2020. AIDS Res Ther. 2021;18:62. https://doi.org/10.1186/s12981-021-00385-5 .
doi: 10.1186/s12981-021-00385-5
pubmed: 34538268
pmcid: 8449993
Holtzman CW, Godfrey C, Ismail L, et al. PEPFAR’s role in protecting and leveraging HIV services in the COVID-19 response in Africa. Curr HIV/AIDS Rep. 2022;19:26–36. https://doi.org/10.1007/s11904-021-00587-6 .
doi: 10.1007/s11904-021-00587-6
pubmed: 34982406
pmcid: 8724594
Vrazo AC, Golin R, Fernando NB, Killam WP, Sharifi S, Phelps, et al. Adapting HIV services for pregnant and breastfeeding women, infants, children, adolescents and families in resource-constrained settings during the COVID-19 pandemic. J Int AIDS Soc. 2020;23(9):e25622.
doi: 10.1002/jia2.25622
pubmed: 32996705
pmcid: 7525801
Johnson and Johnson. Janssen Announces Health Canada Approval of CABENUVA™, the First Long-Acting Regimen for the Treatment of HIV. [Internet]. Johnson and Johnson. https://www.jnj.com/janssen-announces-health-canada-approval-of-cabenuva-the-first-long-acting-regimen-for-the-treatment-of-hiv#:~:text=Cork%2C%20Ireland%2C%20March%2020%2C,HIV%2D1%20infection%20in%20adults .
US FDA. FDA Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection. https://www.fda.gov/drugs/human-immunodeficiency-virus-hiv/fda-approves-cabenuva-and-vocabria-treatment-hiv-1-infection .
EMA. First long-acting injectable antiretroviral therapy for HIV recommended for approval. [Internet]. EMA. 2020. https://www.ema.europa.eu/en/news/first-long-acting-injectable-antiretroviral-therapy-hiv-recommended-approval .
Matama C. CARES, study newsletter A. 2022. [Internet]. https://jcrc.org.ug/jcrc-bulletin-2021-3-2-2/ .
Gilead, Sunlenca
Chandiwana NC, Serenata CM, Owen A, Rannard S, Pérez Casas C, Scott C et al. Impact of long-acting therapies on the global HIV epidemic. AIDS 35(Supplement 2):p S137–43.
PEPFAR. PEPFAR Panorama Spotlight. [Internet]. https://data.pepfar.gov/library .
Ehrenkranz P, Rosen S, Boulle A, Eaton JW, Ford N, Fox MP, Grimsrud A, Rice BD, Sikazwe I, Holmes CB. The revolving door of HIV care: revising the service delivery cascade to achieve the UNAIDS 95-95-95 goals. PLoS Med. 2021;18(5):e1003651. https://doi.org/10.1371/journal.pmed.1003651 . PMID: 34029346; PMCID: PMC8186775.
doi: 10.1371/journal.pmed.1003651
pubmed: 34029346
pmcid: 8186775
Muhoza P, Koffi AK, Anglewicz P, Gichangi P, Guiella G, OlaOlorun F, Omoluabi E, Sodani PR, Thiongo M, Akilimali P, Tsui A, Radloff S. Modern contraceptive availability and stockouts: a multi-country analysis of trends in supply and consumption. Health Policy Plan. 2021;36(3):273–87. https://doi.org/10.1093/heapol/czaa197 . PMID: 33454786; PMCID: PMC8058948.
doi: 10.1093/heapol/czaa197
pubmed: 33454786
pmcid: 8058948
Politi MC, Estlund A, Milne A, et al. Barriers and facilitators to implementing a patient-centered model of contraceptive provision in community health centers. Contracept Reprod Med. 2016;1:21. https://doi.org/10.1186/s40834-016-0032-3 .
doi: 10.1186/s40834-016-0032-3
pubmed: 29201410
pmcid: 5693580
Keddem S, Cronholm PD. Peter MD, MSCE, CAQHPMb,c,d. Barriers and Facilitators to Long-Acting Injectable HIV Pre-Exposure Prophylaxis Implementation in Primary Care Since Its Approval in the United States. JAIDS Journal of Acquired Immune Deficiency Syndromes 95(4):p 370–376, April 1, 2024. https://doi.org/10.1097/QAI.0000000000003370 .
Jenkins SY, Resar D, Panos Z, Staple A, Watkins M, Ripin D, Amole C. Securing accelerated access to long-acting injectable cabotegravir for HIV prevention in low- and middle-income countries. J Int AIDS Soc. 2023;26(Suppl 2):e26101. https://doi.org/10.1002/jia2.26101 . PMID: 37439082; PMCID: PMC10338995.
doi: 10.1002/jia2.26101
pubmed: 37439082
pmcid: 10338995
Ortblad KF, Sekhon M, Wang L, Roth S, van der Straten A, Simoni JM, Velloza J. Acceptability Assessment in HIV Prevention and Treatment Intervention and Service Delivery Research: a systematic review and qualitative analysis. AIDS Behav. 2023;27(2):600–17.
doi: 10.1007/s10461-022-03796-1
pubmed: 35870025
Sued O, Nardi N, Spadaccini L. Key population perceptions and opinions about long-acting antiretrovirals for prevention and treatment: a scoping review. Curr Opin HIV AIDS 17(3):p 145–61.
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
doi: 10.1136/bmj.b2535
pubmed: 19622551
pmcid: 2714657
Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8:19–32.
doi: 10.1080/1364557032000119616
Peters MD, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc. 2015;13(3):141–6.
doi: 10.1097/XEB.0000000000000050
pubmed: 26134548
Goodluck WL, Mwashemele SZ, Urrio R, Naburi H, Kashmir N, Machumi L, et al. Long-term virological outcomes in women who started option B + care during pregnancy for prevention of mother-to-child transmission of HIV in Dar Es Salaam, Tanzania: a cohort study. Lancet HIV. 2021;8(5):e256–65.
doi: 10.1016/S2352-3018(20)30308-8
Kerrigan D, Sanchez Karver T, Muraleetharan O, Savage V, Mbwambo J, et al. A dream come true: perspectives on long-acting injectable antiretroviral therapy among female sex workers living with HIV from the Dominican Republic and Tanzania. PLoS ONE. 2020;15(6):e0234666. https://doi.org/10.1371/journal.pone.0234666 .
doi: 10.1371/journal.pone.0234666
pubmed: 32530939
pmcid: 7292359
Simoni JM, Beima-Sofie K, Wanje G, et al. Lighten this Burden of ours: acceptability and preferences regarding injectable antiretroviral treatment among adults and Youth Living with HIV in Coastal Kenya. J Int Assoc Provid AIDS Care. 2021;20:23.
doi: 10.1177/23259582211000517
Murray M, Antela A, Mills A, Huang J, Jäger H, Bernal E, et al. Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of Cabotegravir and Rilpivirine over 48 weeks. AIDS Behav. 2020;24(12):3533–44.
doi: 10.1007/s10461-020-02929-8
pubmed: 32447500
pmcid: 7667137
Swindells S, Lutz T, Van Zyl L, Porteiro N, Stoll M, Mitha E, et al. Week 96 extension results of a phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment. AIDS. 2022;36(2):185–94.
doi: 10.1097/QAD.0000000000003025
pubmed: 34261093
Chounta V, Overton ET, Mills A, Swindells S, Benn PD, Vanveggel S, et al. Patient-reported outcomes through 1 year of an HIV-1 clinical trial evaluating long-acting cabotegravir and Rilpivirine Administered Every 4 or 8 weeks (ATLAS-2 M). Patient. 2021;14(6):849–62.
doi: 10.1007/s40271-021-00524-0
pubmed: 34056699
pmcid: 8563641
Ba S, Raugi DN, Smith RA, Sall F, Faye K, Hawes SE, et al. A trial of a single-tablet regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 infection in a resource-limited setting: 48-Week results from Senegal, West Africa. Clin Infect Dis. 2018;67(10):1588–94.
doi: 10.1093/cid/ciy324
pubmed: 29672676
pmcid: 6927863
Hodes R, Vale B, Toska E, Cluver L, Dowse R. Ashorn, N. Yummy or Crummy?’ The multisensory components of medicines-taking among HIV-positive youth. Glob Public Health. 2019;14(2):284–99.
doi: 10.1080/17441692.2018.1504103
pubmed: 30067457
Nabitaka VM, Nawaggi P, Campbell J, Conroy J, Harwell J, et al. High acceptability and viral suppression of patients on Dolutegravir-based first-line regimens in pilot sites in Uganda: a mixed-methods prospective cohort study. PLoS ONE. 2020;15(5):e0232419.
doi: 10.1371/journal.pone.0232419
pubmed: 32459822
pmcid: 7252626
Alhassan Y, Twimukye A, Malaba T, Orrell C, Myer L, Waitt C, et al. Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda. BMC Public Health. 2020;20(1):1883.
doi: 10.1186/s12889-020-09991-w
pubmed: 33287795
pmcid: 7720619
Twimukye A, Laker M, Odongpiny EAL, et al. Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda. BMC Infect Dis. 2021;21:1154.
doi: 10.1186/s12879-021-06851-9
pubmed: 34774018
pmcid: 8590364
Musiime V, Fillekes Q, Kekitiinwa A, Kendall L, Keishanyu R, Namuddu R, et al. The pharmacokinetics and acceptability of Lopinavir/Ritonavir Minitab Sprinkles, tablets, and syrups in African HIV-Infected Children. JAIDS J Acquir Immune Defic Syndr. 2014;66(2):148–54.
doi: 10.1097/QAI.0000000000000135
pubmed: 24828266
Kekitiinwa A, Musiime V, Thomason MJ, Mirembe G, Lallemant M, Nakalanzi S, et al. Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected children. Antivir Ther. 2016;21(7):579–85.
doi: 10.3851/IMP3054
pubmed: 27128199
pmcid: 6029664
Pasipanodya B, Kuwengwa R, Prust ML, Stewart B, Chakanyuka C, Murimwa T, et al. Assessing the adoption of lopinavir/ritonavir oral pellets for HIV-positive children in Zimbabwe. J Int AIDS Soc. 2018;21(12):e25214.
doi: 10.1002/jia2.25214
pubmed: 30549217
pmcid: 6293134
Nebot Giralt A, Nöstlinger C, Lee J, et al. Understanding acceptance of and adherence to a new formulation of paediatric antiretroviral treatment in the form of pellets (LPV/r)-A realist evaluation. PLoS ONE. 2019;14(8):e0220408.
doi: 10.1371/journal.pone.0220408
pubmed: 31433803
pmcid: 6703671
Archary M, Zanoni B, Lallemant M, Suwannaprom P, Clarke D, Penazzato M. Acceptability and feasibility of using Raltegravir oral granules for the treatment of neonates in a low-resource setting. Pediatr Infect Dis J. 2020;39(1):57–60.
doi: 10.1097/INF.0000000000002539
pubmed: 31815839
Eshun-Wilson I, Kim HY, Schwartz S, Conte M, Glidden DV, Geng EH. Exploring relative preferences for HIV Service features using Discrete Choice experiments: a synthetic review. Curr HIV/AIDS Rep. 2020;17(5):467–77.
doi: 10.1007/s11904-020-00520-3
pubmed: 32860150
pmcid: 7497362